Oura is set to introduce blood pressure monitoring to its latest wearable devices, the Oura Ring 3 and Oura Ring 4, as part of an upcoming software expansion. The feature will first be made available to select users through the company’s Oura Labs program before receiving full regulatory clearance for public release.
The update will enable the rings to estimate blood pressure trends using photoplethysmography (PPG) sensors, similar to how the devices currently monitor heart rate and sleep. The function will not provide exact diastolic or systolic readings, reflecting its intended role as a general wellness indicator rather than a medical diagnostic tool.
At present, only a small number of consumer devices, such as Huawei’s Watch D and Watch D2, offer clinically certified blood pressure tracking. Nevertheless, companies including Apple, Samsung, and Circular have been developing or promoting similar technology, underscoring the growing competition among health-focused wearables.
Oura’s early access phase will initially be limited to participants in the United States aged 22 and older, with additional restrictions for individuals using pacemakers. This phased rollout allows the company to collect user data and feedback before seeking broader regulatory approval.
With the Oura Ring 3 and 4 priced around $499, the addition of blood pressure monitoring represents another step in expanding the functionality of compact, ring-based health devices. The initiative places Oura alongside leading smartwatch makers in the race to integrate advanced biometric tracking into consumer wearables.
Source: Oura